Alkermes (ALKS) Reports Q4 Earnings: What Key Metrics Have to Say

For the quarter ended December 2025, Alkermes (ALKS) reported revenue of $384.55 million, down 10.6% over the same period last year. EPS came in at $0.46, compared to $1.04 in the year-ago quarter.

The reported revenue represents a surprise of +1.21% over the Zacks Consensus Estimate of $379.96 million. With the consensus EPS estimate being $0.43, the EPS surprise was +7.8%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Alkermes performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- Manufacturing and Royalty revenues: $69.06 million compared to the $71.23 million average estimate based on six analysts. The reported number represents a change of -43.5% year over year.
• Revenues- Product sales, net: $315.49 million versus the six-analyst average estimate of $310.64 million. The reported number represents a year-over-year change of +2.5%.
• Revenues- Proprietary Sales- VIVITROL: $124.1 million versus $122.43 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -7.5% change.
• Revenues- Manufacturing and Royalty Revenues- VUMERITY: $27.62 million compared to the $34.83 million average estimate based on four analysts. The reported number represents a change of -21.1% year over year.
• Revenues- Proprietary Sales- ARISTADA: $97.2 million versus the four-analyst average estimate of $93.77 million. The reported number represents a year-over-year change of +0.6%.
• Revenues- Proprietary Sales- LYBALVI: $94.1 million compared to the $93.91 million average estimate based on four analysts. The reported number represents a change of +22.2% year over year.

View all Key Company Metrics for Alkermes here>>>

Shares of Alkermes have returned -0.4% over the past month versus the Zacks S&P 500 composite's -0.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 
Alkermes plc (ALKS): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research